Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PSD3 antisense RNA 1 (PSD3-AS1) is a putative non-coding RNA assigned as an antisense transcript to the PSD3 gene. There is no direct evidence in peer-reviewed literature for PSD3-AS1 as a characterized molecule, nor any data on its sequence, cellular expression, biological function, disease association, or involvement as a drug target. By contrast, PSD3 (protein-coding) is a known guanine nucleotide exchange factor (GEF) activator of ARF6, implicated in cell cycle regulation, apoptosis, and the pathogenesis of cancer and fatty liver disease. The lack of structured functional, disease, or drug-related data for PSD3-AS1 makes it an unlikely therapeutic target and suggests either misannotation or the need for further foundational research[3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PSD3 antisense RNA 1 (PSD3-AS1).